What is Sarepta Therapeutics Inc (SRPT) stock price today?

Sarepta Therapeutics Inc (SRPT) currently trades at $20.67 per share. The stock has a market capitalization of $2.18B and a P/E ratio of —x.

Is SRPT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Sarepta Therapeutics Inc has a Smart Value Score of 47/100 (Grade C), resulting in a "Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -0.42.

What is Sarepta Therapeutics Inc's revenue and earnings?

Sarepta Therapeutics Inc has trailing twelve-month (TTM) revenue of $2.20B with profit margins of -32.50%. Earnings per share (EPS) is $-7.13.

Is Sarepta Therapeutics Inc financially healthy?

Sarepta Therapeutics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -0.42 places it in the distress.

SRPT

Sarepta Therapeutics Inc

NASDAQ: SRPT · HEALTHCARE · BIOTECHNOLOGY

$20.67

-1.90% today

Updated 2026-04-29

Market cap

$2.18B

P/E ratio

—

P/S ratio

0.99x

EPS (TTM)

$-7.13

Dividend yield

—

52W range

$10 – $65

Volume

2.9M

Market cap

$2.18B

P/E ratio

—

P/S ratio

0.99x

EPS (TTM)

$-7.13

Dividend yield

—

52W range

$10 – $65

Volume

2.9M

WallStSmart proprietary scores

out of 100

Grade: C

Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

2.0

Profitability

4.0

Valuation

2/9

Piotroski F-Score

Weak

-0.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$21.78

+5.37%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy7 Buy13 Hold3 Sell2 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $125.38M — positive

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -0.42 — distress zone

- Thin margins at -32.50%

- Revenue declining -32.70% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$933.01M	$1.24B	$1.90B	$2.20B	$2.20B
Net income	$-703.49M	$-535.98M	$235.24M	$-713.41M	$-282.85M
EPS	—	—	—	—	$-7.13
Free cash flow	$-357.60M	$-588.34M	$-352.74M	$-307.45M	$125.38M
Profit margin	-75.40%	-43.11%	12.37%	-32.45%	-32.50%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SRPT	$2.18B	47	7.3	2.0	4.0	5.0	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Sarepta Therapeutics Inc trades at $20.67. Our Smart Value Score of 47/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.42, it sits in the distress. TTM revenue stands at $2.20B. with profit margins at -32.50%.

Frequently asked questions

What is Sarepta Therapeutics Inc's stock price?

Sarepta Therapeutics Inc (SRPT) trades at $20.67.

Is Sarepta Therapeutics Inc overvalued?

Smart Value Score 47/100 (Grade C, Sell).

What is the price target of Sarepta Therapeutics Inc (SRPT)?

The analyst target price is $21.78, representing +5.4% upside from the current price of $20.67.

What is Sarepta Therapeutics Inc's revenue?

TTM revenue is $2.20B.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-0.42 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.sarepta.com

Quick metrics

P/S ratio0.99x

ROE-53.50%

Beta0.28

50D MA$19.43

200D MA$19.68

Shares out0.11B

Float0.09B

Short ratio—

Avg volume2.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

SRPT vs LLY →SRPT vs JNJ →SRPT vs ABBV →Stock screener →